Delon Hannes Human - 15 Nov 2021 Form 4/A - Amendment Insider Report for Cryomass Technologies, Inc. (CRYM)

Role: Director
Signature: /s/ Delon Hannes Human
Issuer symbol: CRYM
Transactions as of: 15 Nov 2021
Net transactions value: +$152,000
Form type: 4/A - Amendment
Filing time: 18 Nov 2021, 14:44:50 UTC
Date Of Original Report: 15 Nov 2021
Previous filing: 15 Nov 2021
Next filing: 22 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRYM	Common Stock	Purchase	$152,000	+760,000		$0.2000	760,000	15 Nov 2021	By Health Diplomats Pte Ltd	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRYM	Warrants	Purchase		+760,000	+51%		2,260,000	15 Nov 2021	Common Stock	760,000	$0.4000	By Health Diplomats Pte Ltd	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Health Diplomats Pte Ltd is a Singapore exempt private company limited by shares 100% owned by Mr. Human.
F2	The purchase reflects a Unit purchase, each Unit consisting of (a) 10,000 shares of common stock at a price of $0.20 per share and (b) one common stock purchase warrant exercisable to purchase 10,000 additional shares of common stock of the corporation (each such additional share a "Warrant Share") at an exercise price of $0.40 per Warrant Share. For the purposes of this report no purchase price has been attributed to the warrant.

Content

Health Diplomats Pte Ltd is a Singapore exempt private company limited by shares 100% owned by Mr. Human.

The purchase reflects a Unit purchase, each Unit consisting of (a) 10,000 shares of common stock at a price of $0.20 per share and (b) one common stock purchase warrant exercisable to purchase 10,000 additional shares of common stock of the corporation (each such additional share a "Warrant Share") at an exercise price of $0.40 per Warrant Share. For the purposes of this report no purchase price has been attributed to the warrant.